Enhanced levels of the apoptotic BAX/BCL-2 ratio in children with acute lymphoblastic leukemia and high-risk features

Genetics and Molecular Biology

Volumn 36, Issue 1, 2013, Pages 7-11

  Kaparou, Maria ^a   Choumerianou, Despoina ^a   Perdikogianni, Chrysoula ^a   Martimianaki, Georgia ^a   Kalmanti, Maria ^a   Stiakaki, Eftichia ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Leukemia; Protein; Real time PCR analysis

Indexed keywords

COMPLEMENTARY DNA; FAS ANTIGEN; FAS LIGAND; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ISOLATION; CHILD; CHROMOSOME 9P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION;

EID: 84874893689     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572013005000003     Document Type: Article

References (23)

1. Aref S, Salama O, Al-Tonbary Y and Mansour A (2004) Assessment of Bcl-2 expression as modulator of Fas mediated apoptosis in acute leukemia. Hematology 9:113-121
2. Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, Locatelli F, Lo Nigro L, Luciani M, Messina C, et al. (2008) Long-term results of the AIEOP-ALL-95 TRIAL for childhood acute lymphoblastic leukemia: Insight on the prognostic value of DNA Index in the framework of Berlin-Frankfurt-Muenster-based chemotherapy. J Clin Oncol 26:283-289.
3. Baryshnikov AY, Polosukhina ER, Tupitsin NN, Gavrikova NV, Andreeva LY, Zabotina TN, Mayakova SA, Kurmashov VI, Syrkin AB, Kadagidze ZG, et al. (1999) CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukemia patients. Adv Exp Med Biol 457:251-258.
4. Carroll WL, Bhojwani D, Min DJ and Raetz EA (2006) Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer 46:570-578.
5. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Aricò M and Campana D (1996) Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87:1140-1146.
6. Farrow SN and Brown R (1996) New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev 8:1960-1966.
7. Fulda S (2009) Therapeutic opportunities for counteracting apoptosis resistance in childhood leukemia. Br J Haematol 145:441-454.
8. Gala JL, Vermylen C, Cornu G, Ferrant A, Michaux JL, Philippe M and Martiat P (1994) High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis. Ann Haematol 69:17-24.
9. Hacker G (2000) The morphology of apoptosis. Cell Tissue Res 301:5-17.
10. Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC, Nachman JB, Steinherz PG, Hutchinson R, Gaynon PS, et al. (1999) Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 94:1537-1544.
11. Hockenbery DM, Oltavi ZN, Yin XM, Milliman CL and Korsmeyer SJ (1993) Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241-251.
12. Hogarth AL and Hall GA (1999) Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphoblastic leukemia. Blood 93:2671-2678.
13. Nahi H, Hägglund H, Ahlgren T, Bernell P, Hardling M, Karlsson K, Lazarevic VL, Linderholm M, Smedmyr, B, Aström, M, et al. (2008) An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: A multi-center study of 381 patients. Haematologica 93:1734-1738.
14. Narayan S, Chandra J, Sharma M, Naithani R and Sharma S (2007) Expression of apoptosis regulators Bcl-2 and Bax in childhood acute lymphoblastic leukemia. Hematology 12:39-43.
15. Ong YL, McMullin MF, Bailie KE, Lappin TR, Jones FG and Irvine AE (2000) High Bax expression is a good prognostic indicator in acute myeloid leukemia. Br J Haematol 111:182-189.
16. Peters R, Leyraz S and Perey L (1998) Apoptotic regulation in primitive hematopoietic precursors. Blood 92:2041-2052.
17. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig WD, Henze G, Dörken B and Daniel PT (2000) Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14:1606-1613.
18. Pui CH and Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178.
19. Schuler D and Szende B (2004) Apoptosis in acute leukemia. Leuk Res 28:661-666.
20. Winick NJ, Carroll WL and Hunger SP (2004) Childhood leukemia-new advances and challenges. N Engl J Med 351:601-603.
21. Wood CM, Goodman PA, Vassilev AO and Uckun FM (2003) CD95 (APO-1/FAS) deficiency in infant acute lymphoblastic leukemia: Detection of novel soluble Fas splice variants. Eur J Haematol 70:156-171.
22. Wuchter C, Karawajew L, Ruppert V, Schrappe M, Harbott J, Ratei R, Dörken B and Ludwig WD (2000) Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukemia. Br J Haematol 110:54-160.
23. Yang S and Korsmeyer SJ (1996) Molecular thanaptosis: A discourse on bcl-2 family and cell death. Blood 88:386-401.